1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends

US Medical Radiopharmaceuticals Market

  • September 2013
  • 102 pages
  • Frost & Sullivan
Report ID: 1658648


Table of Contents

New Growth Opportunities Emerge in a Strenuous Market

This research service pertains to the US market for medical radiopharmaceuticals. A thorough market sizing and forecasting model of market revenue, procedure volumes, and average pricing is included, along with analyses of market trends, drivers and restraints, and the reimbursement and the competitive environments at the total level as well as within each segment. The three market segments considered are diagnostic SPECT radiopharmaceuticals, diagnostic PET radiopharmaceuticals and therapeutic radiopharmaceuticals. The base year of the study is 2012 and the forecast period extends seven years through 2019.

Executive Summary

•The US medical radiopharmaceuticals market is comprised mostly of mature market segments arising from traditional molecular imaging procedures such as cardiovascular single-photon emission computed tomography (SPECT) imaging using technetium (Tc-99m) and myocardial positron emission tomography (PET) perfusion imaging using fludeoxyglucose (18F-FDG).
•However, with several new radiopharmaceutical products currently in the pipeline for both diagnostic and therapeutic applications, there remains much room for market growth, and growth prospects for the next seven years remain fairly high.
•After continued reimbursement pressure starting with but not limited to the Deficit Reduction Act of 2006, the most recent revisions by the Center of Medicare and Medicaid Services (CMS) has a slightly more positive note.
•In fact, 2013 fee schedule updates provided of an increase in reimbursement levels of between X and X% for both SPECT and PET imaging procedures.
•With the stabilization of molybdenum supply in 2012, after a 3-year phase during 2008 to 2010 characterized by radioisotope shortages and uncertain availability, the US radiopharmaceuticals market is now back on track to recover its lost momentum.
•Owing to ongoing advances both on the side of imaging technology and pharmaceutical research, each of SPECT and PET radiopharmaceuticals are expected to continue to evolve beyond their respective stronghold—cardiology for SPECT and oncology for PET.
•Indeed, the competition between these two modalities continues to intensify in various procedures and indications, particularly with PET imaging making forays into cardiac imaging and gaining higher acceptance among cardiology specialists.
•However, it is the application areas of neurology and oncology that hold the greatest growth potential both for diagnostic and therapeutic radiopharmaceuticals.
•In the case of neurology, new amyloid imaging agents hold high promise in applications such as diagnosing Parkinson's and Alzheimer's diseases. In oncology, one new major therapeutic radiopharmaceutical agent has been developed for treating prostate cancer.

CEO’s Perspective

1. Nuclear medicine and molecular imaging modalities continue to slowly grow in capability and adoption.
2. SPECT radiopharmaceuticals segment revenue reinstate and maintain single-digit growth rates.
3. PET radiopharmaceuticals continue to demonstrate robust growth, making strides into cardiology.
4. Several radiopharmaceuticals currently in development will enter the market during the next five years.
5. Therapeutic radiopharmaceuticals segment takes off starting in 2014, achieving double-digit growth.

Market Overview—Introduction

•Radiopharmaceuticals are used to perform several types of nuclear medicine and molecular imaging procedures in the US primarily in hospitals, but also in various outpatient settings such as cardiology private practices.
•A pioneering country in the field of nuclear medicine and molecular imaging, the US healthcare system maintains the highest rate of utilization of these modalities globally and is at the forefront of technological advances and market adoption in these areas.
•Accordingly, the US market is the single largest radiopharmaceuticals market globally, representing about X% of worldwide market revenues in 2012, although higher growth rates can be observed in certain other European and Asia-Pacific countries.
•Given the severe regulatory limitations for the operation of nuclear reactors on US soil, it follows naturally that Canada continues to be the world’s largest exporter of nuclear products and technology including, but not limited, to medical purposes.
•Canada’s central role in the supply and production chains might start to decrease gradually, however, with the signing into law of the American Medical Isotopes Production Act of 2011 (AMIPA) on January 2, 2013. It is aimed at curtailing the use and export of highly enriched uranium (HEU) for the production of medical isotopes by promoting the alternative use of medical radiopharmaceuticals produced from non-highly enriched uranium.

Distribution Structure and Clinical Applications Discussion

•The clinical end customers for radiopharmaceutical products include nuclear medicine and molecular imaging specialists, as well as various medical specialists in radiology, cardiology, neurology, or oncology, having access to SPECT and PET imaging equipment across hospitals, private practices, and diagnostic imaging centers.
•The two main distribution channels for radiopharmaceuticals include either a radiopharmaceutical precursor shipped alongside a generator or as part of a cold kit. This is then prepared by providers on site, or a ready-to-use radiopharmaceutical dose prepared in and shipped from a radiopharmacy.
•The generator-based channel to market is a more recent one, with only a limited number of industry participants providing these products. For example, only Lantheus Medical Imaging and Covidien (now Mallinckrodt) are currently in the market for technetium generators, while only Bracco currently sells Rubidium generators.
•The types of generators available on the market today do not encompass all radiopharmaceutical agents, and are limited Mo-99/Tc-99m generators, Sr-82/Rb-82 generators, Ge-68/Ga-68 generators, Sr-90/Y-90 generators, and W-188/Re-188 generators.
•In the radiopharmacy model, providers rely on same-day shipping from a geographically close radiopharmacy, of read-to-use radiopharmaceutical does having a relatively short shelf-life.

Market Overview—Scope of Study

•This research service pertains to the US market, with a base year of 2012, and discusses medical radiopharmaceuticals used in nuclear medicine and molecular imaging during diagnostic and therapeutic procedures on humans across US healthcare facilities.
•Not included in the market sizing assessment for the purpose of this study are products that are ancillary to the actual radiopharmaceutical doses, including:
- Nuclear medicine and PET equipment and accessories are used in conjunction with or for the injection of radiopharmaceuticals.
- Adjunct pharmacological (non-radioactive) are agents commonly used alongside radiopharmaceuticals such as dipyridamole, adenosine, regadenoson, dobutamine (used for stress imaging), aminophylline (antidote used to reverse stress agents), and sincalide (used to empty gallbladder hepatobiliary imaging).
- Ancillary products sold as part of cold kits (e.g. ligand, reducing agent, buffer to adjust the pH, and stabilizing agents and excipients) are used on-site for the preparation of radiopharmaceutical injections that can be sold bundled or separately from the associated radioisotope dose.
- Medical devices that use radiopharmaceuticals, such as Yttrium-90 microsphere devices, are specialty products
- Radiopharmaceuticals used during radiotherapy applications such as brachytherapy and radiation therapy (e.g. external beam radiotherapy, intensity-modulated radiation therapy, and image-guided radiation therapy).

Key Questions This Study Will Answer

• Is the recent market slowdown a permanent readjustment of the market, or will the current stability give way to an increasing growth pattern?
• Which segments of the market are most likely to drive market growth back to its historical rates, and over which period of time?
• What are the key radiopharmaceutical products in the market and on the horizon that will stimulate growth in market demand for SPECT and PET radiopharmaceuticals?
• What role are evolving clinical guidelines expected to play in favor or to the detriment of each imaging modality in the current and future market?
• What type of impact is the trend toward personalized medicine expected to have on the evolution of the therapeutic radiopharmaceuticals market?
• What is the outlook on the current industry dynamics and the expected evolution of market concentration around the top five industry participants?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:


The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Angioplasty of arteries of lower extremities for peripheral artery disease. European reimbursement report

  • $ 10450
  • Industry report
  • April 2017
  • by Med Tech Reimbursement Consulting

Report presents summary of the reimbursement situation in Europe for a group of angioplasty procedures of arteries of lower extremities for peripheral artery disease (plain and drug-eluting balloon angioplasty, ...

Frontier Pharma: Head and Neck Cancer - Immunotherapies and Signal Transduction Inhibitors Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • March 2017
  • by GBI Research

Frontier Pharma: Head and Neck Cancer - Immunotherapies and Signal Transduction Inhibitors Dominate First-in-Class Innovation Summary Head and neck cancer (HNC) is the sixth most common malignancy worldwide, ...

Medical Laboratory Testing Services including Cardiac, Molecular Diagnostic and Genomic. Strategies & Trends. Price & Volume Forecasts by Laboratory Department. 2017 to 2022 - Global Version

  • $ 5995
  • Industry report
  • April 2017
  • by Howe Sound Research

“Medical Laboratory Testing Services reaches 12 billion tests per year. Genomic technology and China healthcare expansion driving global growth.....” Report Overview: A market that just keeps on growing. ...


Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.